S 
Shin Nippon Biomedical Laboratories 2395.T · JPY
Health Care · Tokyo Stock Exchange · 🇯🇵 Japan
1,450
+6.46%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in JPY, from our data supplier.
Revenue
¥32.52bn
FY2017FY2026
Net income
¥4.57bn
FY2017FY2026
Free cash flow
¥3.15bn
FY2017FY2026
Shareholders' equity
¥43.12bn
FY2017FY2026
Income statement
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥32.52bn | ¥32.41bn | ¥26.45bn | ¥25.09bn | ¥17.75bn | ¥15.11bn | ¥14.56bn | ¥15.66bn | ¥16.60bn | ¥17.24bn |
| Gross profit | ¥15.83bn | ¥16.57bn | ¥14.28bn | ¥13.05bn | ¥9.69bn | ¥7.55bn | ¥7.62bn | ¥6.18bn | ¥5.20bn | ¥4.36bn |
| Research and development | ¥2.40bn | ¥2.22bn | ¥1.74bn | ¥683.1m | ¥425.1m | ¥392.2m | ¥400.9m | ¥339.8m | ¥518.4m | ¥600.6m |
| Operating income | ¥2.71bn | ¥3.09bn | ¥4.16bn | ¥5.31bn | ¥4.31bn | ¥2.71bn | ¥3.30bn | ¥829.8m | −¥697.5m | −¥401.7m |
| Net income | ¥4.57bn | ¥4.92bn | ¥5.53bn | ¥6.06bn | ¥7.13bn | ¥3.66bn | ¥2.55bn | ¥1.95bn | −¥3.56bn | −¥915.9m |
| Diluted earnings per share | 109.69 | 118.30 | 132.86 | 145.56 | 171.21 | 87.96 | 61.26 | 46.85 | -85.41 | -22.00 |
Balance sheet
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | ¥105.06bn | ¥92.42bn | ¥76.30bn | ¥58.31bn | ¥39.38bn | ¥37.61bn | ¥39.00bn | ¥54.33bn | ¥57.49bn | ¥56.25bn |
| Cash and short-term investments | ¥18.54bn | ¥12.03bn | ¥10.61bn | ¥10.53bn | ¥7.00bn | ¥7.29bn | ¥5.25bn | ¥5.14bn | ¥5.31bn | ¥7.45bn |
| Total liabilities | ¥61.57bn | ¥52.33bn | ¥42.14bn | ¥31.95bn | ¥19.66bn | ¥21.78bn | ¥22.62bn | ¥25.85bn | ¥31.28bn | ¥33.78bn |
| Debt | ¥41.26bn | ¥34.61bn | ¥26.33bn | ¥18.93bn | ¥9.28bn | ¥12.86bn | ¥15.12bn | ¥16.16bn | ¥19.14bn | ¥23.12bn |
| Shareholders' equity | ¥43.12bn | ¥40.02bn | ¥34.11bn | ¥26.21bn | ¥19.56bn | ¥15.73bn | ¥16.29bn | ¥28.41bn | ¥26.16bn | ¥22.45bn |
| Shares outstanding | 42m | 42m | 42m | 42m | 42m | 42m | 42m | 42m | 42m | 42m |
Cash flow
Fiscal years
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | ¥8.33bn | ¥7.04bn | ¥2.11bn | ¥4.00bn | ¥5.95bn | ¥4.75bn | ¥3.02bn | ¥2.89bn | ¥1.34bn | −¥849.8m |
| Capital spending | −¥5.17bn | −¥10.85bn | −¥8.61bn | −¥4.96bn | −¥1.61bn | −¥1.12bn | −¥1.23bn | −¥1.10bn | −¥1.02bn | −¥1.02bn |
| Free cash flow | ¥3.15bn | −¥3.82bn | −¥6.50bn | −¥951.7m | ¥4.34bn | ¥3.63bn | ¥1.79bn | ¥1.79bn | ¥326.0m | −¥1.87bn |
| Dividends paid | −¥2.08bn | −¥2.10bn | −¥2.07bn | −¥2.48bn | −¥826.5m | −¥206.2m | −¥123.6m | −¥123.6m | −¥123.0m | −¥123.0m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ¥7.87bn | ¥11.33bn | ¥6.43bn | ¥8.29bn | ¥6.48bn | ¥10.18bn | ¥9.73bn | ¥6.96bn |
| Gross profit | ¥4.05bn | ¥4.92bn | ¥4.23bn | ¥3.61bn | ¥3.07bn | ¥4.89bn | ¥5.16bn | ¥3.50bn |
| Operating income | ¥521.7m | ¥1.21bn | ¥978.6m | ¥390.2m | −¥340.9m | ¥1.09bn | ¥1.81bn | ¥225.2m |
| Net income | ¥1.06bn | ¥2.30bn | ¥1.21bn | ¥800.7m | ¥260.4m | ¥1.72bn | ¥1.87bn | ¥1.21bn |
| Diluted earnings per share | 25.56 | 55.15 | 29.06 | 19.23 | 6.26 | 41.30 | 45.03 | 29.04 |
| Total assets | ¥100.21bn | ¥105.06bn | ¥113.08bn | ¥90.98bn | ¥89.07bn | ¥92.42bn | ¥97.30bn | ¥88.98bn |
| Cash and short-term investments | ¥14.33bn | ¥18.54bn | ¥15.41bn | ¥11.56bn | ¥11.57bn | ¥12.03bn | ¥10.06bn | ¥11.21bn |
| Debt | ¥19.57bn | ¥40.79bn | ¥18.67bn | ¥37.66bn | ¥11.69bn | ¥34.18bn | ¥10.55bn | ¥34.96bn |
| Shareholders' equity | ¥41.73bn | ¥43.12bn | ¥52.86bn | ¥37.87bn | ¥35.51bn | ¥40.02bn | ¥44.99bn | ¥36.43bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 9.0% | 16.6% | 8.2% |
| Operating income | -20.1% | -0.0% | — |
| Net income | -9.0% | 4.5% | 5.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 49.9% | 51.3% | 51.5% | 45.2% |
| Operating margin | 8.9% | 13.1% | 14.9% | 9.4% |
| Net margin | 14.6% | 18.1% | 21.3% | 15.1% |
Valuation history
At each fiscal year end
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 13.3 | 14.1 | 12.6 | 11.7 | 13.2 | 16.1 | 11.0 | 13.5 | -7.8 | -26.3 |
| Price to sales | 1.9 | 2.1 | 2.6 | 2.8 | 5.3 | 3.9 | 1.9 | 1.7 | 1.7 | 1.4 |
Dividends and splits
Per share, in the currency the company pays
Paid for 7 years. Last went ex-dividend on 29 Sept 2026.
| FY2027 | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 20.00 | 80.00 | 50.00 | 50.00 | 30.00 | 10.00 | 5.00 | 3.00 |
- 2-for-1 split · 27 Sept 2005
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.